摘要
目的探讨丹参多酚酸盐联合鼠神经生长因子治疗脊髓损伤(SCI)的临床疗效及安全性。方法选择医院2015年至2017年收治的急性SCI患者173例,按随机数字表法分为对照组(86例)和治疗组(87例)。两组患者均给予鼠神经生长因子治疗,治疗组患者加用丹参多酚酸盐。两组患者均连续治疗2个月。结果治疗组的总有效率为81. 61%,明显高于对照组的63. 95%(P <0. 01);治疗后,两组运动评分、触觉评分及痛觉评分均明显高于治疗前(P <0. 05),且治疗组明显高于对照组(P <0. 05);两组血清超氧化物歧化酶(SOD)及脑源性神经生长因子(BDNF)水平均明显高于治疗前,血清丙二醛(MDA)及星形胶质原性钙结合蛋白S100β(S100β)水平均明显低于治疗前,且治疗组变化幅度大于对照组(P <0. 05);两组治疗过程中均无严重不良反应发生。结论丹参多酚酸盐联合鼠神经生长因子治疗SCI临床疗效显著,能改善患者的神经功能,减轻氧化应激反应,且安全性好,值得临床推广。
Objective To investigate the clinical effect and safety of salvianolate combined with rat nerve growth factor in the treatment of spinal cord injury(SCI). Methods Totally 173 patients with acute SCI admitted to our hospital from 2015 to 2017 were selected and randomly divided into the control group(n=86) and the treatment group(n=87) according to the random number table method. The control group was treated with rat nerve growth factor, while the treatment group was treated with salvianolate combined with rat nerve growth factor. The two groups were treated for 2 months. Results The total effective rate of the treatment group was 81.61% , which was significantly higher than 63.95% of the control group(P 〈 0. 01). After treatment, the motor score, tactile score and pain score of the two groups were significantly higher than those before treatment(P 〈 0. 05),and those in the treatment group were significantly higher than those in the control group(P 〈 0.05). After treatment,the levels of serum SOD and BDNF in the two groups were significantly higher than those before treatment,while the levels of serum MDA and S10013 in the two groups were significantly lower than those before treatment, and the change in the treatment group was more significant than that in the control group(P 〈 0.05). No serious adverse reactions occurred in the two groups during treatment. Conclusion Salvianolate combined with rat nerve growth factor in the treatment of SCI has significant clinical effect and safety,it can improve the nerve function of patients, reduce oxidative stress reaction,which is worthy of clinical promotion.
作者
赵妍
杨春生
田冲
Zhao Yan;Yang Chunsheng;Tian Chong(The Twelve Division of the First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China 830000;The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China 830054)
出处
《中国药业》
CAS
2018年第22期56-59,共4页
China Pharmaceuticals
基金
新疆维吾尔自治区卫生计生委青年科技人才专项科研项目[2013Y29]